The bad news was with the science in it. I can go as deep into it as you would like. Because it was an adenoviral vector, and we all have antibodies to the adenovirus type-5 vector that was used in the CanSino vaccine, there was a worry that there would be antibodies to the vector itself, the vaccine itself, that we would naturally have already been making. There was a question of how effective that vaccine would be. We provided that information back to them.
When we saw the data later on in the summer, we then recommended that the collaboration end.